Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia

被引:0
|
作者
Bacigalupo, A
vanLint, MT
Valbonesi, M
Lercari, G
Carlier, P
Lamparelli, T
Gualandi, F
Occhini, D
Bregante, S
Valeriani, A
Piaggio, G
Pitto, A
Benvenuto, F
Figari, O
deStefano, G
Caimo, A
Sessarego, M
机构
[1] OSPED SAN MARTINO GENOVA,CATTEDRA MED LEGALE,CTR TRANSFUS,I-16132 GENOA,ITALY
[2] UNIV GENOA,DIPARTIMENTO MED INTERNA,GENOA,ITALY
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thirty-one patients (median age, 44 years) with advanced hematologic malignancies were given thiotepa 15 mg/kg, and cyclophosphamide 120 (n = 14) or 150 (n = 17) mg/kg followed by unfractionated peripheral blood stem cell transplants (PBSCT) from genotypically identical siblings (n = 28) or one antigen mismatched family donor (n = 3). Donors were mobilized with granulocyte colony-stimulating factor 5 to 10 mu g/kg/d for 6 days and underwent two to three leukapheresis on days +5, +6, +7. The median cell yield per donor expressed/kg of recipients body weight was as follows: nucleated cells 13 x 10(8)/kg; CD34(+) cells 6 x 10(6)/kg; colony-forming unit-granulocyte macrophage 38 x 10(4)/kg, and CD3(+) cells 449 x 10(6)/kg. The diagnoses were chronic myeloid leukemia (n = 4), acute myeloid (n = 9) or lymphoid leukemia (n = 2), acute myelofibrosis (n = 2), multiple myeloma (n = 1), lymphoma (n = 6), chronic lymphocytic leukemia (n = 1) myelodysplasia (n = 6). Twenty-eight patients had advanced disease, 29 patients were first grafts, and 2 were second transplants 3 and 9 years after the first. Neutrophil counts of 0.5 x 10(9)/L and platelet counts of 30 x 10(9)/L platelets were both achieved on day +14 (median). Engraftment could be proven by sex markers or DNA polymerphism in 29 of 31 patients: one had early leukemia relapse and one patient was unevaluable because of early death. Acute graft-versus-host disease (GVHD) was scored as minimal or absent (grade 0 to I) in 14 patients, moderate (grade II) in 13, and severe (grade III to IV) in four. Causes of death were leukemia (n = 4), acute GVHD (0 = 4, with associated cytomegalovirus infections in three), sepsis (n = 1), liver failure (n = 1), multiorgan failure (n = 1), and hemorrhage (n = 1). The actuarial transplant mortality is 29%, the actuarial relapse rate 22%. Nineteen patients survive with a median follow up of 288 days (100-690). The actuarial 2-year survival is 57%. Three patients received PBSCT from family donors mismatched for one class II antigen: all engrafted, one developed grade I aGVHD; one died of leukemia on day +155; two are alive disease free 267 to 290 days postgraft. This study suggests that thiotepa cyclophosphamide followed by unfractionated PBSC allograft may be an alternative form of transplant for adults with advanced leukemia, also in the setting of one antigen mismatched donor. The engraftment is rapid with acceptable GVHD and relatively low transplant-related mortality. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:353 / 357
页数:5
相关论文
共 50 条
  • [1] Biological properties of peripheral blood progenitor cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor
    Scott, MA
    Apperley, JF
    Bloxham, DM
    Jestice, HK
    John, S
    Marcus, RE
    Gordon, MY
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (02) : 474 - 480
  • [2] Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia
    Min, YH
    Lee, ST
    Kim, JS
    Jang, JH
    Suh, HC
    Kim, HO
    Hahn, JS
    Ko, YW
    YONSEI MEDICAL JOURNAL, 2001, 42 (01) : 65 - 73
  • [3] Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor
    Gyger, M
    Stuart, RK
    Perreault, C
    BONE MARROW TRANSPLANTATION, 2000, 26 (01) : 1 - 16
  • [4] Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor
    M Gyger
    RK Stuart
    C Perreault
    Bone Marrow Transplantation, 2000, 26 : 1 - 16
  • [5] Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone
    Gaugler, Beatrice
    Arbez, Jessy
    Legouill, Steven
    Tiberghien, Pierre
    Moreau, Philippe
    Derenne, Sophie
    Saas, Philippe
    Mohty, Mohamad
    CYTOTHERAPY, 2013, 15 (07) : 861 - 868
  • [6] Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor
    Bensinger, WI
    Clift, RA
    Anasetti, C
    Appelbaum, FA
    Demirer, T
    Rowley, S
    Sandmaier, BM
    TorokStorb, B
    Storb, R
    Buckner, CD
    STEM CELLS, 1996, 14 (01) : 90 - 105
  • [7] Phenotype of Peripheral Blood Cells Mobilized by Granulocyte Colony-Stimulating Factor in Patients with Chronic Heart Failure
    Konenkov, V. I.
    Pokushalov, E. A.
    Poveshchenko, O. V.
    Kim, I. I.
    Romanov, A. B.
    Guleva, N. A.
    Bernvald, V. V.
    Soloviova, A. O.
    Yankayte, E. V.
    Poveshchenko, A. F.
    Karaskov, A. M.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2012, 153 (01) : 124 - 128
  • [8] Phenotype of Peripheral Blood Cells Mobilized by Granulocyte Colony-Stimulating Factor in Patients with Chronic Heart Failure
    V. I. Konenkov
    E. A. Pokushalov
    O. V. Poveshchenko
    I. I. Kim
    A. B. Romanov
    N. A. Guleva
    V. V. Bernvald
    A. O. Soloviova
    E. V. Yankayte
    A. F. Poveshchenko
    A. M. Karaskov
    Bulletin of Experimental Biology and Medicine, 2012, 153 : 124 - 128
  • [9] Responses of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells to alloantigen stimulation
    Nawa, Y
    Teshima, T
    Sunami, K
    Hiramatsu, Y
    Yano, T
    Shinagawa, K
    Omoto, E
    Harada, M
    BLOOD, 1997, 90 (04) : 1716 - 1718
  • [10] CD34(+) cells mobilized by cyclophosphamide plus granulocyte colony-stimulating factor are functionally different from CD34(+) cells mobilized by granulocyte colony-stimulating factor alone
    Cesana, C
    CarloStella, C
    Mangoni, L
    Regazzi, E
    Garau, D
    Almici, C
    Caramatti, C
    Giachetti, R
    Rizzoli, V
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 264 - 264